Sleeper Diseases: Forecast and Assessment of Neglected Disease Market OpportunitiesCHI Insight Pharma ReportsFebruary 1, 2006 SKU: CHI1219457 |
|
Calming and Sleeping in Latvia
5/8/2012 | published by: Euromonitor International
In Latvia, there was faster growth for standard calming and sleeping products in 2011. The shift towards more expensive and higher quality products was the major contributor to growth in 2011.The trend of younger consumers
|
more...
|
$900.00
|
|
Freedonia Focus on Diabetes Monitoring Products: United States
5/31/2012 | published by: Freedonia Focus
This report discusses US demand for diabetes monitoring products for the years 2006 and 2011, with forecasts for 2016. Topics covered include market size, product and market segmentation, regulatory considerations, product development, market environment, product
|
more...
|
$600.00
|
|
Calming and Sleeping in Dominican Republic
5/9/2012 | published by: Euromonitor International
Calming and sleeping products are becoming increasingly popular due to the stressful lifestyles of consumers, especially those in large cities. Due to the speed of daily life, having to deal with different environments, work, family
|
more...
|
$900.00
|
|
Calming and Sleeping in Guatemala
5/10/2012 | published by: Euromonitor International
Use of OTC calming and sleeping products is limited in the country. The total market size of this category is GTQ850,800, making it one of the smallest categories in the consumer health market in the
|
more...
|
$900.00
|
|
Calming and Sleeping in Ukraine
5/10/2012 | published by: Euromonitor International
Consumers began to return to calming and sleeping products in 2011. The financial crisis contributed to increased usage of home-made traditional/herbal treatments (eg, valerian root) as a way to economise. However, as the economy showed
|
more...
|
$900.00
|
|
Targeted Health and Wellness Foods and Beverages: The U.S. Market and Global Trends
3/1/2012 | published by: Packaged Facts
The market for targeted health and wellness foods and beverages is a dynamic and promising one, driven largely by the growing recognition—among scientists, government, practitioners, and consumers alike—of the instrumental role diet plays in a
|
more...
|
$3,500.00
|
|
Triple Analysis: Breast Cancer, Lymphoma and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Lymphoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria
|
more...
|
$5,175.00
|
|
Triple Analysis: Breast Cancer, Melanoma and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Melanoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria
|
more...
|
$5,175.00
|
|
Triple Analysis: Breast Cancer, Pancreatic Cancer and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Pancreatic Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized
|
more...
|
$5,175.00
|
|
Triple Analysis: Breast Cancer, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Breast Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Each of these three individual parts is
|
more...
|
$5,175.00
|
Related Markets
Behavioral Health Reports
- Key Companies: Depression - Leading players must adapt to remain competitive
- CNS Market Access in China - Investment in mental health services offers growth opportunities for psychiatry players
- Product Profiles: Depression - Next generation vies for second-line patients
- Alcohol Addiction Global Clinical Trials Review, Q2, 2011
- Lifestyle Disorders Market to 2016 - Limited Pipeline Products and Slow Progress in R&D are Major Concerns

